CHF Solutions, Inc. Announces 80% Revenue Growth for its Fourth Quarter and Provides Company Update

EDEN PRAIRIE, Minn., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2018, which included the following highlights:

  • Revenue for the fourth quarter ended December 31, 2018 increased 80.4 percent compared to the same period in 2017. Revenue growth for the year 2018 was 40.7 percent compared to the year 2017.

  • Continued marketing focus into post-cardiovascular surgery and heart failure outpatient clinics.

  • Commenced discussions with the FDA to request a label modification to include pediatrics.

  • Continued international expansion with announcement of new distributor agreements in India and Brazil.

  • Announced the filing of two new patent applications to deepen the company’s intellectual property protection of its Aquadex Flexflow® system.

  • Ended the quarter with $5.5 million in cash and cash equivalents and no debt.

“Our fourth quarter and year-end performance reflects the significant work our team accomplished during 2018. We achieved impressive revenue growth and continued to make strides in our commercialization efforts,” said John Erb, chairman and CEO of CHF Solutions. “I look forward to executing on the additional market opportunities we have identified, which we believe will deliver additional growth in 2019 and beyond.”

The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 4589101. An audio archive of the webcast will be available following the call at

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.  The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the trends in our revenue, our expansion plans to expand into the post-cardiovascular surgery market, our plans for label expansion of Aquadex FlexFlow and our future growth and developments in 2019 and beyond.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our business strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Consolidated Statements of Operations and Comprehensive Loss
 (in thousands, except per share amounts)

  Three months ended
December 31
Twelve months ended
December 31,
  2018 2017    20182017 
Net sales$1,499 $831 $4,998 $3,553 
Costs and Expenses:            
Cost of goods sold 984  851  3,670  2,763 
Selling, general and administrative 3,822  2,692  15,311  10,170 
Research and development 946  479  3,053  1,481 
Goodwill and intangibles impairment   3,951    3,951 
Total costs and expenses 5,752  7,973  22,034  18,365 
Loss from operations (4,253) (7,142) (17,036) (14,812)
Other income (expense):            
Other income, net     10  28 
Warrant valuation expense       (67)
Change in fair value of warrant liability   5    1,475 
Total other income   5  10  1,436 
Loss before income taxes (4,253) (7,137) (17,026) (13,376)
Income tax expense (3)   (6) (6)
Net loss$(4,256)$(7,137)$(17,032)$(13,382)
Basic and diluted loss per share$(8.37)$(140.07)$(42.14)$(525.01)
Weighted average shares outstanding – basic and diluted 509  113  404  48 
Other comprehensive loss:            
Foreign currency translation adjustment$(2)$(1)$(4)$(8)
Total comprehensive loss$(4,258)$(7,138)$(17,036)$(13,390)

Consolidated Balance Sheets
(in thousands, except share and per share amounts)

  December 31,
  December 31,
Current assets       
Cash and cash equivalents  $5,480 $15,595  
Accounts receivable 786  545  
Inventories 1,658  1,588  
Other current assets 203  136  
Total current assets 8,127  17,864  
Property, plant and equipment, net 536  570  
Other assets 113  21  
TOTAL ASSETS$8,776 $18,455  
Current liabilities       
Accounts payable$1,133 $862  
Accrued compensation 1,498  1,021  
Other current liabilities 209  208  
Total current liabilities 2,840  2,091  
Other liabilities   126  
Total liabilities 2,840  2,217  
Commitments and contingencies       
Stockholders’ equity       
Series A junior participating preferred stock as of December 31, 2018 and December 31, 2017, par value $0.0001 per share; authorized 30,000 shares, none outstanding     
Series F convertible preferred stock as of December 31, 2018 and December 31, 2017, par value $0.0001 per share; authorized 535 and 3,780 shares, respectively, issued and outstanding 535 and 3,780, respectively       
Preferred stock as of December 31, 2018 and December 31, 2017, par value
$0.0001 per share; authorized 39,969,465 and 39,966,220 shares, respectively, none outstanding
   —    —  
Common stock as of December 31, 2018 and December 31, 2017, par value
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding
513,445 and 271,357, respectively
Additional paid‑in capital 204,101  197,367  
Accumulated other comprehensive income:       
Foreign currency translation adjustment 1,223  1,227  
Accumulated deficit (199,388) (182,356) 
Total stockholders’ equity 5,936  16,238  

Consolidated Statements of Cash Flows
(in thousands)

  For the years ended December 31,
  2018 2017 
Operating Activities     
Net loss $(17,032)$(13,382)
Adjustments to reconcile net loss to cash flows from operating activities:     
Depreciation and amortization 232 769 
Stock-based compensation expense, net 2,087 499 
Goodwill and intangibles impairment  3,951 
Change in fair value of warrant liability  (1,475)
Warrant valuation expense  67 
Changes in assets and liabilities:     
Accounts receivable (241)(263)
Inventories (70)(911)
Other current assets (67)1 
Other assets (14) 
Accounts payable and accrued expenses 545 (1,176)
Net cash used in operations (14,560)(11,920)
Investing activities:     
Purchase of property and equipment (198)(259)
Net cash used in investing activities (198)(259)
Financing activities:     
Net proceeds from public stock offerings 4,647 24,281 
Net proceeds from exercise of warrants  1,989 
Net proceeds from the sale of preferred stock, common stock and warrants  184 
Net cash provided by financing activities 4,647 26,454 
Effect of exchange rate changes on cash (4)(3)
Net increase (decrease) in cash and cash equivalents (10,115)14,272 
Cash and cash equivalents—beginning of period 15,595 1,323 
Cash and cash equivalents—end of period $5,480 $15,595 
Supplemental schedule of non-cash activities     
  Financing fees incurred for subsequent equity financing included in other assets and accounts payable $78 $ 
  Warrants issued as inducement to warrant exercise $ $509 
  Conversion of temporary equity to permanent equity $ $485 
Supplemental cash flow information       
Cash paid for income taxes $2 $6 


Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.

Bret Shapiro
Managing Partner

Jules Abraham
JQA Partners, Inc.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.